Pantoprazole: 7 things you should know
Feb 03, · Pantoprazole is used to treat erosive esophagitis (damage to the esophagus from stomach acid caused by gastroesophageal reflux disease, or GERD) in adults and children who are at least 5 years old. Pantoprazole is usually given for up to 8 Brand name: Protonix. Jul 26, · Pantoprazole is the generic name for Protonix, a drug that helps treat problems related to acid reflux and peptic ulcers. It works by decreasing acid in the stomach. Pantoprazole is a .
Medically reviewed by Philip Thornton, DipPharm. Last updated on Feb 3, Pantoprazole is a proton pump inhibitor that decreases the amount of acid my in the stomach.
Pantoprazole is used to treat erosive esophagitis damage to the esophagus from stomach acid caused by gastroesophageal reflux diseaseor GERD in adults and children who are at least 5 years old. Pantoprazole is usually given for up to 8 weeks at a time while your esophagus heals. Pantoprazole is also used to treat Zollinger-Ellison syndrome and other what does exodus 4 24 mean involving excess stomach acid.
Pantoprazole is not for the immediate relief of heartburn symptoms. Heartburn is often confused with the first symptoms of a heart attack. Seek emergency medical attention if you have chest pain or heavy feeling, pain spreading to the arm or shoulder, nausea, sweating, and a general ill feeling. Long-term treatment with pantoprazole may also make it harder for your body to absorb vitamin B, resulting in a deficiency of this vitamin.
Talk with your doctor if you need long-term pantoprazole treatment and you have concerns about vitamin B deficiency. Pantoprazole can cause kidney problems. Tell your doctor if you are urinating less than usual, or if you have blood in your urine. Diarrhea may be a sign of a new infection. Call your doctor if you have diarrhea that is watery or has blood in it. Pantoprazole may cause new or worsening symptoms of lupus. Tell your doctor if you have joint pain and a skin rash on your cheeks or arms that worsens in sunlight.
You may be more likely to have a broken pnatozol while taking this medicine long term or more than once per day. Heartburn can mimic early symptoms of a heart attack. Get emergency medical help if you have chest pain that spreads to your jaw or shoulder and you feel anxious or light-headed. You may be more what is pantozol 40 mg used for to have a broken bone while using pantoprazole long-term or more than once per day. Talk with your doctor about ways to keep your bones healthy, especially if you are an adult over It is not known whether this medicine will harm an unborn baby.
Tell your doctor if you panotzol pregnant or plan to become pregnant. Take panntozol exactly as prescribed by your doctor. Follow all directions on your prescription label and read all medication guides or instruction sheets. Use the medicine exactly as directed. Pantoprazole is taken by mouth oral or given as an infusion into what is pantozol 40 mg used for vein injection.
A healthcare provider may teach you how to properly use the injection by yourself. Pantoprazole tablets are taken by mouth, with or without food. The oral granules should mb taken 30 minutes before a meal. The oral granules should be mixed with applesauce or apple juice and given either by mouth or through a nasogastric NG tube. Read and carefully follow any Instructions for Use provided with your medicine. Ask your doctor or pharmacist if you have any questions.
Call your doctor if your symptoms do not improve or if they get worse while you are using this medicine. Pantoprazole can cause false results with certain medical tests. Tell the doctor or laboratory staff that you are using this medicine. Pantoprazole may also affect a drug-screening urine test and you may have false results.
Tell the laboratory staff that you use this medicine. Treatment of Erosive Esophagitis: 40 mg orally once a day for up to 8 weeks; however an additional 8 weeks may be considered for patients who have not healed after the initial wyat. Safety and efficacy beyond 16 weeks of therapy have not been established. Maintenance of Healing of Erosive Esophagitis: 40 mg orally once a gm. Controlled studies have been limited to 12 months of pantoprazole therapy.
Parenteral: 40 mg once a day for 7 to 10 days, administered via intravenous infusion over a period of 15 minutes. Intravenous therapy should be discontinued as soon as the patient is able to resume oral therapy. Oral: 40 mg orally once a day, for short-term administration up to 8 weeks ; however an additional 8 weeks may what to use to clean windows inside considered for patients who have not healed after the initial treatment.
Parenteral: 80 mg every 12 hours, administered by minute infusion. Daily doses higher than mg administered in equally divided doses by minute infusion, or administered for more than 6 days have not been studied. Oral: 40 mg twice daily, to a maximum of mg per day. What is pantozol 40 mg used for patients have received treatment with pantoprazole for more than 2 years.
Use pnatozol medicine as soon as you can, but skip the missed dose if it is almost time for your next dose. Do not use two doses at one time. This medicine can cause diarrhea, which may be a sign of a new infection. If you have diarrhea that is watery or bloody, call your doctor. Do not use anti-diarrhea medicine unless your doctor tells you to.
Get emergency medical help if you have signs of an allergic reaction to pantoprazole: hives ; difficulty breathing; swelling of how to remove stains from white leather couch face, lips, tongue, or throat.
Taking pantoprazole long-term may cause you to develop stomach growths called fundic gland polyps. Talk with your doctor about this risk. If you use pantoprazole for longer than 3 years, you could develop a vitamin B deficiency. Talk to your doctor about how to manage this condition if you develop it. This is not a complete list of side effects and others may occur.
Call your doctor for medical advice about side effects. Tell your doctor about all your other medicines. Some may interact with pantoprazole, especially:.
This list is not complete. Other drugs may affect pantoprazole, including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible drug interactions are listed here. Take pantoprazole tablets immediately before a what to do on captiva island fl, preferably in the morning.
Pantoprazole tablets may be taken with food or on an empty stomach. Swallow the tablet whole. Do not crush, break, or chew the tablet. Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use pantoprazole what is pantozol 40 mg used for for the indication prescribed.
Always consult your healthcare provider to ensure the information displayed on this page applies to what does racial diversity mean personal circumstances. Detailed Pantoprazole dosage information. Pantoprazole side id more detail. Pantoprazole drug interactions more detail. When should you take pantoprazole? Drug Status Availability Prescription only Rx.
Pantoprazole sodium delayed-release tablets USP are indicated for: Short-Term Treatment of Erosive Esophagitis Associated With Gastroesophageal Reflux Disease (GERD) Pantoprazole sodium delayed-release tablets USP are indicated in adults for the short-term treatment (up to 8 weeks) in the healing and symptomatic relief of erosive esophagitis. Uses. Pantoprazole is used to treat certain stomach and esophagus problems (such as acid reflux). It works by decreasing the amount of acid your stomach makes. This medication relieves symptoms. Jul 16, · Pantoprazole oral tablet is used to reduce the amount of stomach acid your body makes. It helps treat painful symptoms caused by conditions such as .
Pantoprazole sodium delayed-release tablets USP are indicated in adults for the short-term treatment up to 8 weeks in the healing and symptomatic relief of erosive esophagitis. For those adult patients who have not healed after 8 weeks of treatment, an additional 8 week course of pantoprazole sodium delayed-release tablets USP may be considered. Safety of treatment beyond 8 weeks in pediatric patients has not been established. Pantoprazole sodium delayed-release tablets USP are indicated for maintenance of healing of erosive esophagitis and reduction in relapse rates of daytime and nighttime heartburn symptoms in adult patients with GERD.
Controlled studies did not extend beyond 12 months. Pantoprazole sodium delayed-release tablets USP are indicated for the long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome. Pantoprazole sodium is supplied as delayed-release tablets. The recommended dosages are outlined in Table 1. Doses up to mg daily have been administered. Maintenance of Healing of Erosive Esophagitis.
Adults 40 mg Once daily. Directions for method of administration are presented in Table 2. Table 2: Administration Instructions. Pantoprazole sodium delayed-release tablets should be swallowed whole, with or without food in the stomach. If patients are unable to swallow a 40 mg tablet, two 20 mg tablets may be taken.
Concomitant administration of antacids does not affect the absorption of pantoprazole sodium delayed-release tablets. Pantoprazole sodium delayed-release tablets are contraindicated in patients with known hypersensitivity to any component of the formulation [see Description 11 ] or any substituted benzimidazole.
Symptomatic response to therapy with pantoprazole does not preclude the presence of gastric malignancy. Atrophic gastritis has been noted occasionally in gastric corpus biopsies from patients treated long-term with pantoprazole, particularly in patients who were H. Generally, daily treatment with any acid-suppressing medications over a long period of time e.
Rare reports of cyanocobalamin deficiency occurring with acid-suppressing therapy have been reported in the literature. This diagnosis should be considered if clinical symptoms consistent with cyanocobalamin deficiency are observed. Published observational studies suggest that PPI therapy like pantoprazole may be associated with an increased risk of Clostridium difficile associated diarrhea, especially in hospitalized patients. This diagnosis should be considered for diarrhea that does not improve [see Adverse Reactions 6.
Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated. Several published observational studies suggest that proton pump inhibitor PPI therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist, or spine.
The risk of fracture was increased in patients who received high-dose, defined as multiple daily doses, and long-term PPI therapy a year or longer. Patients at risk for osteoporosis-related fractures should be managed according to established treatment guidelines [see Dosage and Administration 2 and Adverse Reactions 6. Hypomagnesemia, symptomatic and asymptomatic, has been reported rarely in patients treated with PPIs for at least three months, in most cases after a year of therapy.
Serious adverse events include tetany, arrhythmias, and seizures. In most patients, treatment of hypomagnesemia required magnesium replacement and discontinuation of the PPI.
For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia e. Due to the chronic nature of GERD, there may be a potential for prolonged administration of pantoprazole. In long-term rodent studies, pantoprazole was carcinogenic and caused rare types of gastrointestinal tumors. The relevance of these findings to tumor development in humans is unknown [see Nonclinical Toxicology In high-dose methotrexate administration, a temporary withdrawal of the PPI may be considered in some patients [see Drug Interactions 7.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. Safety in nine randomized comparative U.
The most frequently occurring adverse reactions are listed in Table 3. Safety of pantoprazole in the treatment of Erosive Esophagitis EE associated with GERD was evaluated in pediatric patients ages 1 year through 16 years in three clinical trials.
Safety trials involved pediatric patients with EE; however, as EE is uncommon in the pediatric population, pediatric patients with endoscopically-proven or symptomatic GERD were also evaluated.
All adult adverse reactions to pantoprazole are considered relevant to pediatric patients. For safety information in patients less than 1 year of age see Use in Specific Populations 8. The following adverse reactions seen in adults in clinical trials were not reported in pediatric patients in clinical trials, but are considered relevant to pediatric patients: photosensitivity reaction, dry mouth, hepatitis, thrombocytopenia, generalized edema, depression, pruritus, leukopenia, and blurred vision.
The following adverse reactions have been identified during postapproval use of pantoprazole. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Concomitant use of atazanavir or nelfinavir with proton pump inhibitors is not recommended. Coadministration of atazanavir or nelfinavir with proton pump inhibitors is expected to substantially decrease atazanavir or nelfinavir plasma concentrations and may result in a loss of therapeutic effect and development of drug resistance.
There have been postmarketing reports of increased INR and prothrombin time in patients receiving proton pump inhibitors, including pantoprazole, and warfarin concomitantly. Increases in INR and prothrombin time may lead to abnormal bleeding and even death. Patients treated with proton pump inhibitors and warfarin concomitantly should be monitored for increases in INR and prothrombin time. Concomitant administration of pantoprazole and clopidogrel in healthy subjects had no clinically important effect on exposure to the active metabolite of clopidogrel or clopidogrel-induced platelet inhibition [see Clinical Pharmacology No dose adjustment of clopidogrel is necessary when administered with an approved dose of pantoprazole.
Pantoprazole causes long-lasting inhibition of gastric acid secretion. Therefore, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability e. There have been reports of false positive urine screening tests for tetrahydrocannabinol THC in patients receiving proton pump inhibitors. An alternative confirmatory method should be considered to verify positive results.
However, no formal drug interaction studies of Methotrexate with PPIs have been conducted [see Warnings and Precautions 5. Reproduction studies have been performed in rats at oral doses up to 88 times the recommended human dose and in rabbits at oral doses up to 16 times the recommended human dose and have revealed no evidence of impaired fertility or harm to the fetus due to pantoprazole.
There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed [see Nonclinical Toxicology Pantoprazole and its metabolites are excreted in the milk of rats.
Pantoprazole excretion in human milk has been detected in a study of a single nursing mother after a single 40 mg oral dose. The clinical relevance of this finding is not known. Many drugs which are excreted in human milk have a potential for serious adverse reactions in nursing infants. Based on the potential for tumorigenicity shown for pantoprazole in rodent carcinogenicity studies, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the benefit of the drug to the mother.
The safety and effectiveness of pantoprazole for short-term treatment up to eight weeks of erosive esophagitis EE associated with GERD have been established in pediatric patients 1 year through 16 years of age. Effectiveness for EE has not been demonstrated in patients less than 1 year of age. In addition, for patients less than 5 years of age, there is no appropriate dosage strength in an age-appropriate formulation available.
Therefore, pantoprazole is indicated for the short-term treatment of EE associated with GERD for patients 5 years and older. The safety and effectiveness of pantoprazole for pediatric uses other than EE have not been established. Use of pantoprazole in pediatric patients 1 year through 16 years of age for short-term treatment up to eight weeks of EE associated with GERD is supported by: a extrapolation of results from adequate and well-controlled studies that supported the approval of pantoprazole for treatment of EE associated with GERD in adults, and b safety, effectiveness, and pharmacokinetic studies performed in pediatric patients [see Clinical Studies Safety of pantoprazole in the treatment of EE associated with GERD in pediatric patients 1 through 16 years of age was evaluated in three multicenter, randomized, double-blind, parallel-treatment studies, involving pediatric patients, including 8 with EE 4 patients ages 1 year to 5 years and 4 patients 5 years to 11 years.
All 4 of these patients with EE were healed Hetzel-Dent score of 0 or 1 at 8 weeks. Because EE is uncommon in the pediatric population, predominantly pediatric patients with endoscopically-proven or symptomatic GERD were also included in these studies.
Patients were treated with a range of doses of pantoprazole once daily for 8 weeks. For safety findings see Adverse Reactions 6.
Because these pediatric trials had no placebo, active comparator, or evidence of a dose response, the trials were inconclusive regarding the clinical benefit of pantoprazole for symptomatic GERD in the pediatric population. The effectiveness of pantoprazole for treating symptomatic GERD in pediatric patients has not been established.
Although the data from the clinical trials support use of pantoprazole for the short-term treatment of EE associated with GERD in pediatric patients 1 year through 5 years, there is no commercially available dosage formulation appropriate for patients less than 5 years of age [see Dosage and Administration 2 ]. In a population pharmacokinetic analysis, clearance values in the children 1 to 5 years old with endoscopically proven GERD had a median value of 2.
Following a 1. Pantoprazole was not found to be effective in a multicenter, randomized, double-blind, placebo-controlled, treatment-withdrawal study of pediatric patients 1 through 11 months of age. Patients were enrolled if they had symptomatic GERD based on medical history and had not responded to non-pharmacologic interventions for GERD for two weeks.
Patients received pantoprazole daily for four weeks in an open-label phase, then patients were randomized in equal proportion to receive pantoprazole treatment or placebo for the subsequent four weeks in a double-blind manner. Efficacy was assessed by observing the time from randomization to study discontinuation due to symptom worsening during the four-week treatment-withdrawal phase.
There was no statistically significant difference between pantoprazole and placebo in the rate of discontinuation. These doses resulted in pharmacodynamic effects on gastric but not esophageal pH. Following once daily dosing of 2.
Following once daily dosing of approximately 1. Because pantoprazole was not shown to be effective in the randomized, placebo-controlled study in this age group, the use of pantoprazole for treatment of symptomatic GERD in infants less than 1 year of age is not indicated. In short-term U. The incidence rates of adverse reactions and laboratory abnormalities in patients aged 65 years and older were similar to those associated with patients younger than 65 years of age. Erosive esophagitis healing rates in the women treated with pantoprazole sodium delayed-release tablets in U.
In the women treated long-term with pantoprazole 40 mg or 20 mg, healing was maintained at a rate similar to that in men.
The incidence rates of adverse reactions were also similar for men and women. Spontaneous postmarketing reports of overdose are generally within the known safety profile of pantoprazole. Pantoprazole is not removed by hemodialysis. In case of overdosage, treatment should be symptomatic and supportive.